Danaher Aktie
| 218,49USD | -0,44USD | -0,20% |
WKN: 866197 / ISIN: US2358511028
Personal
| 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 80 000 | 81 000 | 63 000 | 63 000 | 0 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0,37 | 0,39 | 0,38 | 0,38 | 0,00 |
Bilanz (in Mio. USD) - Aktiva
| 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 11 648 | 15 883 | 13 937 | 9 497 | 12 756 |
| Summe Anlagevermögen | 71 536 | 68 467 | 70 551 | 68 045 | 70 708 |
| Summe Aktiva | 83 184 | 84 350 | 84 488 | 77 542 | 83 464 |
Bilanz (in Mio. USD) - Passiva
| 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Summe Fremdkapital | 38 007 | 34 260 | 30 998 | 27 992 | 30 923 |
| Summe Eigenkapital | 45 177 | 50 090 | 53 490 | 49 550 | 52 541 |
| Summe Passiva | 83 184 | 84 350 | 84 488 | 77 542 | 83 464 |
Adresse
| 2200 Pennsylvania Avenue North West, 20037-1701 Washington | |
| Telefon | +1 (202) 828-0850 |
| Internet | http://www.danaher.com |
Management
|
A. Shane Sanders
Independent Director |
|
Alan G. Spoon
Independent Director |
|
Alex de Winter
Vice President-New Ventures |
|
Charles W. Lamanna
Independent Director |
|
Christopher M. Bouda
Chief Accounting Officer & Vice President |
|
Daniel A. Raskas
Senior Vice President-Corporate Development |
|
Elias A. Zerhouni
Independent Director |
|
Feroz Dewan
Independent Director |
|
Georgeann F. Couchara
Senior Vice President-Human Resources |
|
Greg Milosevich
Executive Vice President-Life Sciences business |
|
Jai Shankar Krishnan
Vice President-High Growth Markets |
|
James F. O'Reilly
Secretary, Chief Sustainability Officer & SVP |
|
Jessica L. Mega
Independent Director |
|
John Bedford
Vice President-Investor Relations |
|
John T. Schwieters
Independent Director |
|
Jonathan B. Leiken
Senior Vice President & General Counsel |
|
Jose-Carlos Gutiérrez-Ramos
Chief Science Officer & Senior Vice President |
|
Julie Sawyer Montgomery
Executive Vice President-Diagnostics |
|
Linda Hefner Filler
Lead Independent Director |
|
Maria A. Khoury
Group CFO-Biotechnology & Life Sciences |
|
Martin Stumpe
Chief Technology & AI Officer |
|
Matthew R. McGrew
Chief Financial Officer & Executive Vice President |
|
Mitchell P. Rales
Director |
|
Rainer M. Blair
President, Chief Executive Officer & Director |
|
Raymond C. Stevens
Independent Director |
|
Sadik Kassim
Chief Technology Officer |
|
Steven Dee
Chief Technology Officer |
|
Steven M. Rales
Chairman |
|
Teri L. List-Stoll
Independent Director |
|
Travis Taylor
Manager-Investor Relations |
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.